Fig. 1

Multivariable association of all-cause mortality and cardiovascular events after dialysis initiation among patients with incident end-stage renal disease (ESRD) due to dialysis-requiring acute kidney injury (AKI-D), patients with incident ESRD not due to AKI-D, and patients with AKI-D who recovered. Models are adjusted for the following baseline covariates: age, gender, race, Hispanic ethnicity, smoking status, acute myocardial infarction, heart failure, ischemic stroke or transient ischemic attack, peripheral artery disease, mitral and/or aortic valvular disease, atrial flutter or fibrillation, venous thromboembolism, other thromboembolic events, coronary artery bypass surgery, percutaneous coronary intervention, diabetes mellitus, hypertension, dyslipidemia, hyperthyroidism, hypothyroidism, cirrhosis, chronic lung disease, diagnosed dementia, diagnosed depression, hospitalized bleed, body mass index, systolic blood pressure, eGFR, dipstick proteinuria, hemoglobin level, HDL cholesterol level, LDL cholesterol level, and pre-admission receipt of the following medications: ACE inhibitor, angiotensin II receptor blocker, antiarrhythmic drug, beta blocker, calcium channel blocker, diuretic, alpha blocker, any anti-hypertensive agent, aldosterone receptor antagonist, nitrates, vasodilators, statin, other lipid-lowering agent, non-aspirin antiplatelet agent, low molecular weight heparin, non-steroidal anti-inflammatory drug, and diabetic therapy